Thompson Davis & Co’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Thompson Davis & Co’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,000	Closed	-$39K	–	1191
2015 Q4	$39K	Hold	5,000	–	–	0.06%	299
2015 Q3	$42K	Hold	5,000	–	–	0.06%	298
2015 Q2	$55K	Buy	5,000 +2,000	+67%	+$25.7K	0.06%	289
2015 Q1	$42K	Hold	3,000	–	–	0.05%	330
2014 Q4	$51K	Buy	+3,000	New	+$43.7K	0.06%	283

Other funds holding INFI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Thompson Davis & Co's INFI Position: Q1 2016 in Review

Thompson Davis & Co sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2016, closing a stake of 5,000 shares — an estimated $39K sold.

Thompson Davis & Co first reported a position in INFI in Q4 2014 and held it in 5 quarters. The position peaked at $55K in Q2 2015. 117 funds tracked by Wall St. Rank hold INFI as of Q1 2016.

Thompson Davis & Co reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Thompson Davis & Co sold 5,000 Infinity Pharmaceuticals, Inc. shares in Q1 2016, an estimated $39K.
Thompson Davis & Co first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
Thompson Davis & Co's Infinity Pharmaceuticals, Inc. position peaked at $55K in Q2 2015.
117 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.